A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the
anthrax toxin are provided. In one aspect, human
peripheral blood cells that have been pre-exposed to
anthrax toxin are used in the SCID mouse model. This method results in high human
antibody titers which are primarily of the IgG
isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of
anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and / or treating anthrax infection comprising a binding agent that prevents the
assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax
contamination are also described.